Published: August 2023. Next review: 2028.
Diabetes has been recognised as a condition that increases morbidity and mortality risk in people infected with COVID-19. Therefore, diabetes identification and treatment are critical to optimal outcomes in people with the virus. All people infected with COVID-19 (with or without diabetes) and requiring dexamethasone have an elevated risk of developing hyperglycaemia. These people require blood glucose monitoring and in some cases a change to treatment.
This document supports the development of localised guidelines on optimal diabetes care for people with COVID-19.
Consideration of existing protocols, resources and expertise are recommended for the identification and management of diabetes in hospitalised patients.
As highlighted within the document, the Australian Diabetes Society Guide for the Management of Diabetes during the COVID-19 pandemic provides content for consideration in service delivery and the COVID-19 Infection Prevention and Control Manual provides guidance on the various levels of COVID-19 transmission risk.
Download the Inpatient management of diabetes in people with COVID-19guide (PDF 296.2 KB)